Evidence map›Paper›PMID 37012282›Full record

ArticleScientific reports2023

Analysis of fatality impact and seroprevalence surveys in a community sustaining a SARS-CoV-2 superspreading event.

Enrico Richter, Dominik Liebl, Bianca Schulte, Nils Lehmann, Christine Fuhrmann, Karl-Heinz Jöckel, John P A Ioannidis, Hendrik Streeck

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Flaws and uncertainties in pandemic global excess death calculations.European journal of clinical investigation · 2023
    Review
  3. Article
  4. The end of the COVID-19 pandemic.European journal of clinical investigation · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Enrico RichterInstitute of Virology, University Hospital, University of Bonn, Bonn, Germany.
Dominik LieblInstitute of Finance and Statistics and Hausdorff Center for Mathematics, University of Bonn, Bonn, Germany.
Bianca SchulteInstitute of Virology, University Hospital, University of Bonn, Bonn, Germany.
Nils LehmannInstitute of Medical Informatics, Biometry und Epidemiology (IMIBE), University Hospital Essen, Essen, Germany.
Christine FuhrmannClinical Study Core Unit, Study Center Bonn (SZB), Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
Karl-Heinz JöckelInstitute of Medical Informatics, Biometry und Epidemiology (IMIBE), University Hospital Essen, Essen, Germany.
John P A IoannidisDepartments of Medicine, of Epidemiology and Population Health, of Biomedical Data Science, and of Statistics, Stanford University, Stanford, USA.
Hendrik StreeckInstitute of Virology, University Hospital, University of Bonn, Bonn, Germany. Hendrik.Streeck@ukbonn.de.
University of Bonn · DEInstitut für Medizinische Informatik, Biometrie und Epidemiologie · DEStanford University · USUniversity Hospital Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an ongoing debate on the COVID-19 infection fatality rate (IFR) and the impact of COVID-19 on overall population mortality. Here, we addressed these issues in a community in Germany with a major superspreader event analyzing deaths over time and auditing death certificates in the community.18 deaths that occurred within the first six months of the pandemic had a positive test for SARS-CoV-2. Six out of 18 deaths had non-COVID-19 related causes of death (COD). Individuals with COVID-19 COD typically died of respiratory failure (75%) and tended to have fewer reported comorbidities (p = 0.029). Duration between first confirmed infection and death was negatively associated with COVID-19 being COD (p = 0.04). Repeated seroprevalence essays in a cross-sectional epidemiological study showed modest increases in seroprevalence over time, and substantial seroreversion (30%). IFR estimates accordingly varied depending on COVID-19 death attribution. Careful ascertainment of COVID-19 deaths is important in understanding the impact of the pandemic.

Indexed as

COVID-19SARS-CoV-2Cross-Sectional StudiesGermanyHumansSeroepidemiologic Studies

Identifiers

PMID37012282
PMCPMC10069345
OpenAlexW4362520918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.